Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
Fate Therapeutics Inc
FATE | US
1.22
USD0.09
7.96%
FATE | US
Loading StockChartView...
About Fate Therapeutics Inc
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
25/03/2026
Close
1.22
Open
1.15
High
1.28
Low
1.15
Fate Therapeutics Inc. a clinical-stage biopharmaceutical company develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma and FT522 to treat lymphoma and autoimmune disorders; and CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego California.
View LessFATE | US
Risk
77.7
Sharpe
0.25
Luna's Score
52/100
Recommendation
Hold
Luna says (FATE | US)
What's Working
Strength based on increasing price with high volume
Low Debt to Asset (< 0.2)
Value Stock (Price to Book < 3)
Strong Revenue Growth (> 10%)
What's not Working
High 6-Month Volatility (>65%)
Microcap (<300M USD)
High Market Beta (> 0.8)
Weak Operating Margin (< 10%)
Weak Sharpe Ratio (< 0.3)
Volatility Signals
Bearish: Increased Volatility (6-month > 1-month volatility)
Risk Meter
Loading RiskMeterView...
10 days
68.0%1 month
77.7%3 months
79.5%6 months
88.9%Returns
Loading ReturnMeterView...
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
0.93
Debt to equity
0.25
Debt to assets
0.19
Ent. to EBITDA
-2.59
Ent. to rev.
13.28
PEG
-
Other Fundamentals
EBITDA
-163.44M
MarketCap
138.93M
MarketCap(USD)
138.93M
Div. yield
-
Op. margin
-665.73
Erngs. growth
-
Rev. growth
625.80
Ret. on equity
-42.10
Short ratio
13.95
Short perc.
14.29
Market Sentiment (SMA and Price signals)
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
SMAs: Stock Price Trends
Loading MovingAverageView...
Range10D
0.26
Range1M
0.66
Range3M
0.73
Volumes: Market Activity
Volume Averages
Loading VolumeAverageView...
Rel. volume
1.19
Price X volume
2.48M
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -2.59 | 0.53 | Cheaper |
| Ent. to Revenue | 13.28 | 3,967.00 | Cheaper |
| PE Ratio | - | 41.03 | - |
| Price to Book | 0.93 | 15.55 | Cheaper |
| Dividend Yield | - | 2.20 | - |
| Std. Deviation (3M) | 79.53 | 72.80 | Par |
| Debt to Equity | 0.25 | -1.23 | Expensive |
| Debt to Assets | 0.19 | 0.25 | Cheaper |
| Market Cap | 138.93M | 3.66B | Emerging |
